MYD88 and ovarian carcinoma: demonstrated thatmiR-21 and miR-146a can influence the regulatory role of myeloid differentiation factor 88 (MyD88) in the toll-like receptor 4 (TLR4) pathway in ovarian cancer by inhibiting MyD88 translation (47).